NYSEArca - Delayed Quote USD

ALPS Medical Breakthroughs ETF (SBIO)

31.91 +0.31 (+0.99%)
At close: April 22 at 3:55 PM EDT

Top 10 Holdings (31.42% of Total Assets)

SymbolCompany% Assets
VKTX
Viking Therapeutics, Inc. 5.25%
CERE
Cerevel Therapeutics Holdings, Inc. 4.68%
PCVX
Vaxcyte, Inc. 4.51%
RVMD
Revolution Medicines, Inc. 3.24%
ALKS
Alkermes plc 2.76%
AXSM
Axsome Therapeutics, Inc. 2.31%
ACLX
Arcellx, Inc. 2.24%
CRNX
Crinetics Pharmaceuticals, Inc. 2.23%
SWTX
SpringWorks Therapeutics, Inc. 2.22%
XENE
Xenon Pharmaceuticals Inc. 1.98%

Sector Weightings

SectorSBIO
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Stocks 100.01%
Bonds 0.00%

Equity Holdings

Price/Earnings 0
Price/Book 0.25
Price/Sales 0.1
Price/Cashflow 0
Median Market Cap --
3 Year Earnings Growth --

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

ETF Summary

The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

ETF Overview

Category Health
Fund Family ALPS
Net Assets 115.56M
YTD Daily Total Return -3.14%
Yield 0.20%
Legal Type Exchange Traded Fund

Related Tickers